Phase II study of 5-azacytidine in sarcomas of bone
Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were re...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1982-08, Vol.5 (4), p.411-416 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 4 |
| container_start_page | 411 |
| container_title | American journal of clinical oncology |
| container_volume | 5 |
| creator | Srinivasan, U Reaman, G H Poplack, D G Glaubiger, D L LeVine, A S |
| description | Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity. |
| doi_str_mv | 10.1097/00000421-198208000-00011 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_198208000_00011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6180626</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-9b945299b993829142d68eaa1e50d31ce9b6f200d17ab0fe6f59fa5c38c711943</originalsourceid><addsrcrecordid>eNo9j9tKxDAQhnOhrOvqIwh5gehM0pwuZfFQWNALvQ5pmmDFtkvTvahPb9c9DAw_M8M38BFCEe4RrH6AfRUcGVrDwcwDmxvxgiyBa82EFvyKXOf8Pa-lAr0gC4UGFFdLIt6_fI60LGked_VE-0Ql878-TGNTN12kTUezH0Lf-rw_Vn0Xb8hl8j853h5zRT6fnz7Wr2zz9lKuHzcsCISR2coWkts5rDDcYsFrZaL3GCXUAkO0lUocoEbtK0hRJWmTl0GYoBFtIVbEHP6Goc95iMlth6b1w-QQ3F7dndTdWd39q8_o3QHd7qo21mfw6C3-AIfHU_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II study of 5-azacytidine in sarcomas of bone</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Srinivasan, U ; Reaman, G H ; Poplack, D G ; Glaubiger, D L ; LeVine, A S</creator><creatorcontrib>Srinivasan, U ; Reaman, G H ; Poplack, D G ; Glaubiger, D L ; LeVine, A S</creatorcontrib><description>Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity.</description><identifier>ISSN: 0277-3732</identifier><identifier>DOI: 10.1097/00000421-198208000-00011</identifier><identifier>PMID: 6180626</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Azacitidine - administration & dosage ; Azacitidine - adverse effects ; Bone Neoplasms - drug therapy ; Drug Administration Schedule ; Drug Evaluation ; Female ; Humans ; Leukocyte Count ; Male ; Neoplasm Metastasis ; Neutropenia - chemically induced ; Osteosarcoma - drug therapy ; Platelet Count ; Sarcoma, Ewing - drug therapy ; Thrombocytopenia - chemically induced</subject><ispartof>American journal of clinical oncology, 1982-08, Vol.5 (4), p.411-416</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-9b945299b993829142d68eaa1e50d31ce9b6f200d17ab0fe6f59fa5c38c711943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6180626$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Srinivasan, U</creatorcontrib><creatorcontrib>Reaman, G H</creatorcontrib><creatorcontrib>Poplack, D G</creatorcontrib><creatorcontrib>Glaubiger, D L</creatorcontrib><creatorcontrib>LeVine, A S</creatorcontrib><title>Phase II study of 5-azacytidine in sarcomas of bone</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Azacitidine - administration & dosage</subject><subject>Azacitidine - adverse effects</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Neoplasm Metastasis</subject><subject>Neutropenia - chemically induced</subject><subject>Osteosarcoma - drug therapy</subject><subject>Platelet Count</subject><subject>Sarcoma, Ewing - drug therapy</subject><subject>Thrombocytopenia - chemically induced</subject><issn>0277-3732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j9tKxDAQhnOhrOvqIwh5gehM0pwuZfFQWNALvQ5pmmDFtkvTvahPb9c9DAw_M8M38BFCEe4RrH6AfRUcGVrDwcwDmxvxgiyBa82EFvyKXOf8Pa-lAr0gC4UGFFdLIt6_fI60LGked_VE-0Ql878-TGNTN12kTUezH0Lf-rw_Vn0Xb8hl8j853h5zRT6fnz7Wr2zz9lKuHzcsCISR2coWkts5rDDcYsFrZaL3GCXUAkO0lUocoEbtK0hRJWmTl0GYoBFtIVbEHP6Goc95iMlth6b1w-QQ3F7dndTdWd39q8_o3QHd7qo21mfw6C3-AIfHU_Q</recordid><startdate>198208</startdate><enddate>198208</enddate><creator>Srinivasan, U</creator><creator>Reaman, G H</creator><creator>Poplack, D G</creator><creator>Glaubiger, D L</creator><creator>LeVine, A S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198208</creationdate><title>Phase II study of 5-azacytidine in sarcomas of bone</title><author>Srinivasan, U ; Reaman, G H ; Poplack, D G ; Glaubiger, D L ; LeVine, A S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-9b945299b993829142d68eaa1e50d31ce9b6f200d17ab0fe6f59fa5c38c711943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Azacitidine - administration & dosage</topic><topic>Azacitidine - adverse effects</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Neoplasm Metastasis</topic><topic>Neutropenia - chemically induced</topic><topic>Osteosarcoma - drug therapy</topic><topic>Platelet Count</topic><topic>Sarcoma, Ewing - drug therapy</topic><topic>Thrombocytopenia - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Srinivasan, U</creatorcontrib><creatorcontrib>Reaman, G H</creatorcontrib><creatorcontrib>Poplack, D G</creatorcontrib><creatorcontrib>Glaubiger, D L</creatorcontrib><creatorcontrib>LeVine, A S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Srinivasan, U</au><au>Reaman, G H</au><au>Poplack, D G</au><au>Glaubiger, D L</au><au>LeVine, A S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of 5-azacytidine in sarcomas of bone</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1982-08</date><risdate>1982</risdate><volume>5</volume><issue>4</issue><spage>411</spage><epage>416</epage><pages>411-416</pages><issn>0277-3732</issn><abstract>Eight patients with osteogenic sarcoma and seven patients with Ewing's sarcoma, all with advanced metastatic disease refractory to conventional therapy, were treated with 5-azacytidine (NSC-102816) intravenously at a dosage of 150 mg/m2 in three divided doses daily X 5 days. The courses were repeated q 4 weeks and the dosage was escalated to 200 mg/m2/day, as tolerated. Fourteen patients were evaluable for response. Major toxicities wee hematologic and gastrointestinal. 5-azacytidine had no demonstrable antitumor activity.</abstract><cop>United States</cop><pmid>6180626</pmid><doi>10.1097/00000421-198208000-00011</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1982-08, Vol.5 (4), p.411-416 |
| issn | 0277-3732 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_198208000_00011 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Azacitidine - administration & dosage Azacitidine - adverse effects Bone Neoplasms - drug therapy Drug Administration Schedule Drug Evaluation Female Humans Leukocyte Count Male Neoplasm Metastasis Neutropenia - chemically induced Osteosarcoma - drug therapy Platelet Count Sarcoma, Ewing - drug therapy Thrombocytopenia - chemically induced |
| title | Phase II study of 5-azacytidine in sarcomas of bone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T10%3A13%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%205-azacytidine%20in%20sarcomas%20of%20bone&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=Srinivasan,%20U&rft.date=1982-08&rft.volume=5&rft.issue=4&rft.spage=411&rft.epage=416&rft.pages=411-416&rft.issn=0277-3732&rft_id=info:doi/10.1097/00000421-198208000-00011&rft_dat=%3Cpubmed_cross%3E6180626%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6180626&rfr_iscdi=true |